Amgen Inc. (AMGN) Position Increased by Washington Trust Bank
Washington Trust Bank boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,882 shares of the medical research company’s stock after buying an additional 759 shares during the period. Washington Trust Bank’s holdings in Amgen were worth $1,185,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. Raymond James Trust N.A. raised its position in shares of Amgen by 3.7% in the first quarter. Raymond James Trust N.A. now owns 41,035 shares of the medical research company’s stock valued at $6,733,000 after buying an additional 1,461 shares in the last quarter. Weaver C. Barksdale & Associates Inc. raised its position in shares of Amgen by 26.5% in the first quarter. Weaver C. Barksdale & Associates Inc. now owns 8,576 shares of the medical research company’s stock valued at $1,407,000 after buying an additional 1,798 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in shares of Amgen during the first quarter valued at approximately $230,000. Indiana Trust & Investment Management CO raised its position in shares of Amgen by 12.1% in the first quarter. Indiana Trust & Investment Management CO now owns 2,454 shares of the medical research company’s stock valued at $403,000 after buying an additional 265 shares in the last quarter. Finally, Cardinal Capital Management Inc. bought a new position in shares of Amgen during the first quarter valued at approximately $550,000. Institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded up 1.38% on Wednesday, hitting $172.38. 678,725 shares of the stock traded hands. The firm’s 50-day moving average is $174.35 and its 200 day moving average is $167.93. The firm has a market cap of $125.78 billion, a P/E ratio of 15.70 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 earnings per share. Equities research analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.71%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Position Increased by Washington Trust Bank” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/amgen-inc-amgn-position-increased-by-washington-trust-bank/1496060.html.
Several equities analysts have recently commented on the stock. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Argus upped their price objective on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. UBS AG set a $180.00 price objective on shares of Amgen and gave the stock a “hold” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $174.00 price objective (up from $172.00) on shares of Amgen in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.20% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.